P
MRNA icon

&Partners’s Moderna MRNA Stock Holding History

&Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$483K Buy
6,902
+456
+7% +$23.6K ﹤0.01% 1842
2026
Q1 		$332K Buy
+6,446
New +$301K ﹤0.01% 1929
2022
Q1 		– Sell
-900
Closed -$229K – 201
2021
Q4 		$229K Hold
900
– – 0.14% 157
2021
Q3 		$346K Hold
900
– – 0.22% 106
2021
Q2 		$211K Buy
+900
New +$161K 0.14% 167

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

&Partners's MRNA Position: Q2 2026 in Review

&Partners increased its Moderna (MRNA) stake by 7.1% in Q2 2026, buying an estimated $23.6K and bringing the position to 6,902 shares worth $483K. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

&Partners first reported a position in MRNA in Q2 2021 and has held it in 5 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • &Partners held 6,902 shares of Moderna worth $483K as of Q2 2026.
  • &Partners bought 456 Moderna shares in Q2 2026, an estimated $23.6K.
  • Moderna made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1842 holding.
  • &Partners first reported a position in Moderna in Q2 2021 and has held it in 5 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.